26-Apr-2024
No headlines found.
CooperCompanies Announces First Quarter 2024 Results
Globe Newswire (Thu, 29-Feb 4:15 PM ET)
CooperCompanies 4-for-1 Stock Split Effective Friday (2/16)
Globe Newswire (Thu, 15-Feb 4:15 PM ET)
Cord Blood Registry (CBR) by CooperSurgical and Fulgent Genetics Launch Innovative Genetic Testing
PRNewswire (Fri, 9-Feb 8:31 AM ET)
The Cooper Companies is one of the largest eye care companies in the U.S. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business and is composed of a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and clariti, Cooper controls roughly a quarter of the U.S. contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the U.S., and controls 17% of the U.S. IUD market.
Cooper Companies trades on the NASDAQ stock market under the symbol COO.
As of April 26, 2024, COO stock price declined to $88.84 with 1,009,159 million shares trading.
COO has a beta of 1.24, meaning it tends to be more sensitive to market movements. COO has a correlation of 0.40 to the broad based SPY ETF.
COO has a market cap of $17.66 billion. This is considered a Large Cap stock.
Last quarter Cooper Companies reported $932 million in Revenue and $.85 earnings per share. This beat revenue expectation by $16 million and exceeded earnings estimates by $.07.
In the last 3 years, COO stock traded as high as $115.90 and as low as $61.05.
The top ETF exchange traded funds that COO belongs to (by Net Assets): VTI, VOO, VO, SPY, VUG.
COO has underperformed the market in the last year with a price return of -6.2% while the SPY ETF gained +26.8%. COO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -6.3% and -7.6%, respectively, while the SPY returned +4.5% and -1.9%, respectively.
COO support price is $88.69 and resistance is $91.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that COO stock will trade within this expected range on the day.